GrantRover ↗

← Alle Förderungen

National Institutes of Health · USA

Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)

Offen

Die Einreichungsfrist endet am 2. Juni 2027. Antragsberechtigte Gruppen laut Quelle: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, County governments, Public and State controlled institutions of higher education und 12 weitere.

Frist
2. Juni 2027 (in 199 Tagen)
Fördersumme
Nicht angegeben — siehe offizielle Ausschreibung
Förderquote
Kein Pflicht-Eigenanteil angegeben; Förderquote nicht angegeben
Eigenanteil
Nicht erforderlich
Wahrscheinliche Antragstellende
Gemeinnützige, Hochschulen & Forschung, Öffentliche Stellen, KMU / Start-ups, Unternehmen Aus Quellkategorien oder Programmregeln; maßgeblich ist die Ausschreibung.
Fördergeber
National Institutes of Health
Referenz
PAR-25-211
Assistance Listing (USA)
93.121 Oral Diseases and Disorders Research; 93.213 Research and Training in Complementary and Integrative Health; 93.313 NIH Office of Research on Women's Health; 93.393 Cancer Cause and Prevention Research; 93.866 Aging Research
Zuletzt geprüft
13. November 2026

Offizielle Ausschreibung öffnen ↗ Frist zum Kalender hinzufügen

Die offiziellen Beschreibungen sind in der Sprache des Fördergebers (meist Englisch); Zusammenfassung und Eckdaten auf dieser Seite sind auf Deutsch.

Über diese Ausschreibung

The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions using a milestone-driven, biphasic award mechanism, R61/R33 Phased Innovation Award. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses.

The first phase, funded by the R61, will providing for up to 2 years to identify unique host biological patterns (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with heterogeneity of probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33, will support studies to assess the ability of the unique patterns determined in the R61 phase to detect the improvement of probiotic responsiveness in rigorously designed mechanistic studies in relevant animal models or in human subjects.

Vollständigen Text lesen

The combined R61/R33 should not exceed 5 years. Transition from the R61 to the R33 phase of the award will be administratively reviewed and will be determined based on successful completion of Transition Milestones that need to be clearly specified in the R61 phase application.

Support for a single phased award that does not need the R61 Exploratory phase is available in the companion (R33) NOFO, PAR-AT-24-XXX (TEMP-25413).

Wer kann sich bewerben?

Other Eligible Applicants include the following:

Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Antragstellerkategorien sind nur ein Ausgangspunkt. Über die Antragsberechtigung entscheidet die offizielle Ausschreibung.

Themen

Education Health

So bewerben Sie sich

  1. Read the full notice of funding opportunity (NOFO) linked from the official page: eligibility, cost sharing and evaluation criteria.
  2. Make sure your organisation has an active SAM.gov registration and Unique Entity ID (UEI); registration can take several weeks.
  3. For NIH: the organisation and the principal investigator also need eRA Commons accounts; applications are usually submitted through Grants.gov (for example with ASSIST).
  4. Prepare the required forms, narrative, budget and attachments exactly as the NOFO specifies.
  5. Submit before the deadline and keep the tracking number. Check for amendments before you submit.

From the call text

Who can apply
Not stated in the call text we hold — check the official page
Company stage
Not stated in the call text we hold — check the official page
Single applicant or consortium
Not stated in the call text we hold — check the official page
Where applicants must be based
Not stated in the call text we hold — check the official page
Where to apply
Not stated in the call text we hold — check the official page

Kontakt

National Institutes of Health · grantsinfo@nih.gov · 301-402-2541

Offizielle Quellen

Offizielle Ausschreibungsseite · Programmseite des Fördergebers

Die Angaben auf dieser Seite stammen aus der offiziellen Quelle und wurden zuletzt am 13. November 2026 geprüft. Maßgeblich sind immer die Unterlagen des Fördergebers einschließlich späterer Änderungen.

Weitere Ausschreibungen: National Institutes of Health

National Institutes of Health USA

Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High… (R34 Clinical Trial Required)

PAR-25-274

The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychologic…

National Institutes of Health USA

Investigator Initiated Clinical Trials of Complementary and Integrative… (R01 Clinical Trial Required)

PAR-25-268

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy…

National Institutes of Health USA

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)

PAR-25-158

This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The inten…